Immunogenicity refers to the property that can stimulate the body's immune system to form specific antibodies or sensitize lymphocytes. The evaluation of immunogenicity is closely related to the development of biological drugs. Proteins, antibodies, conjugated peptides and oligonucleotides involved in biological therapy can induce harmful immune responses in the body, leading to the production of anti-drug antibodies (ADAs), which can potentially threaten patient safety of life (causing allergies, autoimmune and other adverse reactions). Among them, anti-drug antibodies with neutralizing ability are called neutralizing antibodies (NAbs). Neutralizing antibodies can reduce the efficacy of biological drugs by inhibiting their biological activity. Immunogenicity testing is divided into two parts: anti-drug antibody and neutralizing antibody testing and evaluation.
At present, the commonly used computational antibody design platforms are mainly Discovery Studio and Rosetta developed from protein structure simulation, and Schrdinger developed from chemical drug structure simulation.
|Project name||Immunogenicity assessment|
|Our services||CD ComputaBio offers immunogenicity assessment service to meet the specific needs of different customers.|
|Timeline||Decide according to your needs.|
|Deliverable||We provide you with raw data and prediction results.|
CD ComputaBio provides professional immunogenicity assessment service to meet the specific needs of regular customers on time and according to budget. CD ComputaBio relies on world-class technical expertise, we provide customers with the best quality one-stop immunogenicity assessment service, including the development of scientific procedures according to different solution needs.Please feel free to contact us for more detailed information, our scientists will tailor the most reasonable plan for your project. If you want to know more service prices or technical details, please feel free to contact us.